In 2016, Mike Goguen left Sand Hill Road after twenty years as one of Sequoia Capital's top-performing investors. He moved to Whitefish, Montana, and built a firm of his own.
He did it quietly. He did it patiently. And he did it on a thesis most of his peers were still dismissing — that the Stanford genomic sequencing project had converted the human body from analog to digital, and that a new category of company would emerge at the intersection of deep technology and the life sciences. The firms that had spent thirty years backing software were about to have to learn biology. Mike, a technologist turned board member of two Sequoia biotech home runs, already had.
A decade later, Two Bear Capital is quietly compounding. The portfolio is working. The platform is deepening. And the thesis — once heretical — now reads as obvious.
What follows is the firm, in pictures and numbers.
"I can teach deal-making to a PhD. I can't teach molecular engineering, cognitive science, or structural biology to an MBA."
At Sequoia, Mike made 54 investments over two decades. 26 crossed $100M in exit value, 11 crossed $500M, 6 crossed $1B, and 3 crossed $10B — a cadence the best venture partners spend a career trying to approximate. His final two Sequoia investments, Guardant Health and StemCentrx, together returned more than any other pair on the firm's book that year. Both were biotech bets Sequoia had to be dragged into making. Mike did the dragging.
80% of the companies on the Forbes Cloud 100 today run on infrastructure shaped by a Mike-led investment. The platforms that move the world's data — NetScreen, Nimble, Arista — carry his fingerprints. Two Bear Capital is the next decade of that work, moved upstream to where the body becomes the platform.
Mike's last two Sequoia investments — Guardant Health and StemCentrx — were biotech deals the firm resisted making. They became two of the best exits of that vintage. Every generalist VC in the valley now follows the same thesis. Most started in 2022. Mike started in 2016.
Two Bear's investment team are PhDs in molecular biology, oncology, cybersecurity, networking, and AI. Mike writes the thesis. The partners read the science. The operators know what a Series A company actually has to do to reach Series B.
Every investment is lead. Every board seat is active. Every company is expected to be defensible on both axes — technical depth and commercial discipline. No tourists. No spray-and-pray. No passive syndicate positions.
Sector targets, Fund II: Enterprise Tech 50% · Biotech 35% · HealthTech 15% | Stage: Seed 15% · Series A 80% · Series B 5%
New TBC capital deployed in year five: $9.25M. Cascade of downstream value created: $382M. Implied multiple on new capital: 41.3×.
Two Bear Capital led every round in Fund I. Lead investor. Lead board seat. Active management from first check to exit. No syndicate-only positions, no tourist investments.
Representative Mike-led investments: Arista Networks, Nimble Storage, NetScreen, Bouncy Castle, PGP Corporation, Guardant Health, StemCentrx, Palo Alto Networks (early), Barracuda Networks.
Sector mix across Funds I and II: Enterprise tech ~65% · Biopharma ~35% · Every investment Seed to Series B · All lead positions.
At one point I dragged him out of bed at 4:30 in the morning to jump on a call with a CFO who was very nervous about signing a big contract with us. Mike was very willing to jump on, explain why — as an investor — he had such confidence in what we were building, and then back that up with a willingness to backstop from an investment perspective. That has always stuck with me. And I see now the way the rest of the Two Bear team is willing to jump in.
Once Silicon Valley Bank was actually in the process of failing, we didn't know how we were going to get through it — and they came forth with a line of credit to allow us to immediately make payroll for our employees. To me, that really is a mark of Two Bear as a standalone high-integrity group that really made a difference in our company.
It's the coaching and the guidance — how to build a company, how to build a successful company. I can pick up the phone and call Mike anytime, even on the weekends. I call him if I'm concerned about something.
Other VC firms would straight out tell you they want to focus on low-hanging fruit. In my conversation with Mike Goguen, he said we should focus on hard-to-treat cancers. I don't know if people understand how different that is from other VC firms — but he told me otherwise. Two Bear Capital gave me the confidence to double down and invest into an idea that I didn't think would reach such high potential.
Founder referrals are now a primary source of Two Bear Capital deal flow — a structural moat that no competing firm can replicate. Elisity declined a $450M acquisition offer. Leapfrog is advancing to MD Anderson-recommended Phase 1b/2a trials. Graphiant beat Cisco for Vodafone at one-fifteenth the price.
Additional world-class outside advisors include Nobel Laureate immunologist James Allison, PhD; Padmanee Sharma, MD, PhD (Oncology); John Delaney, PhD (formerly Biologics R&D, Amgen); Mike Elmore (CISO, GSK); and Larry McEvoy, MD.
Seven Fund II positions already in book: Montara Tx, Talus Bio, QuSecure, Gravwell, Conceal, Rainfall Health, Revenium.